Consolato Francesco, De Fusco Maurizio, Schaeffer Céline, Pieruzzi Federico, Scolari Francesco, Gallieni Maurizio, Lanzani Chiara, Feriozzi Sandro, Rampoldi Luca
Molecular Genetics of Renal Disorders Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
Nephrology and Dialysis Unit, ASST-Monza, San Gerardo Hospital and School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Mol Genet Metab Rep. 2022 Oct 31;33:100926. doi: 10.1016/j.ymgmr.2022.100926. eCollection 2022 Dec.
Anderson-Fabry Disease (FD) is an X-linked lysosomal disorder caused by mutations in the gene encoding the lysosomal hydrolase α-galactosidase A (α-Gal A), leading to accumulation of glycosphingolipids in the lysosomes. FD is a multisystemic disorder leading to progressive cardiovascular, cerebrovascular and kidney dysfunction. Phenotypes are divided in two main classes, classic or non-classic, depending on substrate accumulation, age at onset, disease manifestation, severity and progression. The more severe classical phenotype is generally associated with mutations leading to absent or strongly reduced α-Gal A activity, while mutations with higher residual activity generally lead to the non-classical one. Approximately 70% of the over 1,000 Fabry disease-associated mutations are missense mutations, some leading to endoplasmic reticulum (ER) retention of mutant protein. We hypothesized that such mutations could be associated, besides the well-known absence of α-Gal A function/activity, to a possible gain of function effect due to production of a misfolded protein. We hence expressed α-Gal A missense mutations in HEK293 cells and investigated the localization of mutant protein and induction of ER stress and of the unfolded protein response (UPR). We selected a panel of 7 missense mutations, including mutants shown to have residual or no activity . Immunofluorescence analysis showed that mutants with residual activity have decreased lysosomal localization compared with wild type, and partial retention in the ER, while missense mutants with no residual activity are fully retained in the ER. UPR (ATF6 branch) was significantly induced by all but two mutants, with clear correlation with the extent of ER retention and the predicted mutation structural effect. These data identify a new molecular pathway, associated with gain of function effect, possibly involved in pathogenesis of FD.
安德森-法布里病(FD)是一种X连锁溶酶体疾病,由编码溶酶体水解酶α-半乳糖苷酶A(α-Gal A)的基因突变引起,导致糖鞘脂在溶酶体中蓄积。FD是一种多系统疾病,可导致进行性心血管、脑血管和肾功能障碍。根据底物蓄积情况、发病年龄、疾病表现、严重程度和进展情况,其表型分为两个主要类别,即经典型或非经典型。较严重的经典表型通常与导致α-Gal A活性缺失或大幅降低的突变相关,而具有较高残余活性的突变通常导致非经典表型。在1000多个与法布里病相关的突变中,约70%是错义突变,其中一些导致突变蛋白在内质网(ER)中滞留。我们推测,除了众所周知的α-Gal A功能/活性缺失外,此类突变可能还与因错误折叠蛋白的产生而导致的功能获得效应有关。因此,我们在人胚肾293(HEK293)细胞中表达了α-Gal A错义突变,并研究了突变蛋白的定位以及内质网应激和未折叠蛋白反应(UPR)的诱导情况。我们选择了一组7个错义突变,包括已显示具有残余活性或无活性的突变体。免疫荧光分析表明,与野生型相比,具有残余活性的突变体溶酶体定位减少,部分滞留在内质网中,而无残余活性的错义突变体则完全滞留在内质网中。除两个突变体外,所有突变体均显著诱导了UPR(ATF6分支),且与内质网滞留程度和预测的突变结构效应明显相关。这些数据确定了一条与功能获得效应相关的新分子途径,可能参与了FD的发病机制。